Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapymTOR inhibitors in advanced renal cell carcinomaAxitinib for the management of metastatic renal cell carcinomaAxitinib in the treatment of renal cell carcinoma: patient selection and perspectivesBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinomaCytoreductive surgery in the era of targeted molecular therapyCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewCytoreductive nephrectomy and its role in the present-day period of targeted therapy.Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Role of immunotherapy for renal cell cancer in 2011Differentiating mTOR inhibitors in renal cell carcinomaIndividualising treatment choices in a crowded treatment algorithmCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaPredictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinomaSunitinib in the treatment of metastatic renal cell carcinomaMedical treatment of renal cancer: new horizonsEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaHost type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cellsEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibRenal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkersEfficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasisPredicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
P2860
Q21198871-8C384114-5F89-426A-9E74-6EDE8332B6FEQ24612127-B9219F75-8074-412D-A6A3-05B0C9C7CBFAQ24613720-2745E6B6-AD37-4069-AEF2-49A59C110BA7Q26751341-F135801D-A1E7-4F64-A9EE-148350EB174FQ26766240-CF728F28-2B91-4823-B3D8-AB4AB8EC2CEDQ26772206-5E2BF485-BB56-43BA-B82E-D8B3FCC360E4Q26773653-C5ACEE8C-C3E9-47F2-A4AF-460893C43DDCQ26774134-91CD330C-BD06-4B27-B633-F6F816F3C90CQ26774515-E2076E69-800C-4D2F-9F54-21EB95586540Q26783520-AA261B47-515C-430D-AF44-1CB4BE10DA03Q26825512-55C0BF30-DF71-482E-9186-2F22DD9D1764Q26853453-ED6D140D-D4F0-4B1F-8DF0-3F8477734E2AQ26860172-26D0848D-6972-4AE2-8A6B-E093DA327514Q27023669-56CB6899-B2F5-4EA8-BEF8-4CBB03C00959Q27023770-ED9F126B-B6FF-4A52-B6E9-8F571BB71CA8Q27028048-A530A6BB-3AA2-4CBB-91FA-D40896C7B613Q27851979-B6394520-A67F-42AF-B6E5-840DC1187515Q28067482-F361484A-C8EE-4D7C-9233-EAC0471E8D1DQ28072057-61BE0D57-F72A-4CBE-B02B-2456C56F57E8Q28073174-B94B09AB-FCEF-4F8C-AC3D-B7AD51F95060Q28079861-C4CA41E0-FF5D-4584-849E-445AFE8C0C91Q28247085-FC503B3C-0839-4344-9146-16CBD72F7614Q28248489-19D4061A-6872-410B-8AED-392322B6DEDBQ28765488-553624C6-10B2-4923-B673-804DAFF14EA4Q30235364-0955E5F6-3E61-4410-8E95-483CCB164B7DQ30248354-AE73029E-6312-4899-B707-53A74EA4CDF3Q30382892-1496FB79-B612-4F0E-A7FF-4179A84C6EEBQ30472042-D0C15EE4-19A1-4CDC-9AAA-AEF323CAC72FQ31122505-3E9F0C4B-C138-465D-8F51-2C9A5A99A042Q33166002-1F0FED81-7ACC-4136-81D9-96F5DA5A2360Q33294127-E5E3B726-3A2A-4652-BC70-598EAD3219C1Q33317794-10314831-9263-4E2C-9062-99245F167C91Q33391978-0B165012-CF0C-44ED-87AA-8352F034E35DQ33395466-7C1E55C2-E078-41F5-A7C7-C01B1E56EA50Q33396613-9A996B8F-7696-4B18-A5EA-152BFA4BBE24Q33396965-B9103E84-2666-4DA8-945E-DDC714916C6FQ33398317-D1D978AC-1CC2-4BED-89D3-EF7F29521D7DQ33399152-D54B88B8-18E5-450A-AFEF-4A100155EB54Q33404146-4A88646B-AC1C-4B37-A796-F3D55B18A27FQ33406542-AEA6513D-93EB-4ACD-A47D-C43C8F5D993B
P2860
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@en
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@nl
type
label
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@en
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@nl
prefLabel
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@en
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@nl
P2093
P356
P1476
Interferon-alfa as a comparati ...... advanced renal cell carcinoma.
@en
P2093
Barbara A Murphy
Jennifer Bacik
Madhu Mazumdar
Paul Russo
P304
P356
10.1200/JCO.20.1.289
P407
P577
2002-01-01T00:00:00Z